Oluyemi Okupe on M&A
From $HIMS Hims & Hers Health Q1 2026 Earnings Conference Call · · EARNMOAR
“At the time of closing of Eucalyptus, we expect to make a payment of approximately 240 million with remaining guaranteed consideration and earnout payments extending through early 2029. Importantly, the flexible structure of the transaction gives us the ability to satisfy a meaningful portion of obligations after closing in either cash or stock, which we believe supports long-term balance sheet flexibility.”
On , Oluyemi Okupe, Chief Financial Officer at HIMS & HERS HEALTH INC, spoke about M&A during $HIMS Hims & Hers Health Q1 2026 Earnings Conference Call on EARNMOAR.
About Oluyemi Okupe
During the company's first quarter 2026 earnings call on May 11, 2026, Oluyemi Okupe, chief financial officer of Hims & Hers Health, discussed a strategic pivot in the weight loss specialty that he said was made in March. Okupe stated that the pivot created near-term financial noise but was intended to unlock potential for platform acceleration at scale. He noted that the company incurred approximately $33 million in restructuring costs, primarily consisting of writedowns related to the compounded GLP‑1 supply chain. Okupe described near-term margin headwinds expected in the second quarter as the majority of the weight loss specialty moves toward one‑month shipments. He projected a meaningful step‑up in adjusted EBITDA dollars in the third and fourth quarters, driven by monthly cohorts and operating leverage in G&A, and said the company's primary financial objective is to continue growing while generating strong free cash flow to move quickly on market opportunities. Okupe also indicated that strong growth is expected internationally, but that a meaningful acceleration in the U.S. business is anticipated as certain revenue recognition dynamics clear.